(firstQuint)Risk Adapted Therapy in Diffuse Large B Cell Lymphoma.

 objectives: 1.

 To compare the response rates and toxicity of R-CHOP versus DA-EPOCH-R in untreated CD20+ diffuse large B-cell lymphomas.

 2.

 To compare the event-free survival of R-CHOP versus DA-EPOCH-R chemotherapy in untreated CD20+ diffuse large B-cell lymphomas.

 3.

 To develop predictors of outcome of R-CHOP and DA-EPOCH-R chemotherapy.

.

 Risk Adapted Therapy in Diffuse Large B Cell Lymphoma@highlight

This randomized phase II trial is studying two different combination chemotherapy regimens to compare how well they work in treating patients with diffuse large B-cell lymphoma.

